University of Central Florida

STARS
Electronic Theses and Dissertations, 2004-2019
2009

The Expression Of Mkrn1, An E3 Ubiquitin Ligase For Telomerase
Reverse Transcriptase, Is Induced With Differentiation Therapy In
Leukemia
Jose Salvatico
University of Central Florida

Part of the Microbiology Commons, and the Molecular Biology Commons

Find similar works at: https://stars.library.ucf.edu/etd
University of Central Florida Libraries http://library.ucf.edu
This Masters Thesis (Open Access) is brought to you for free and open access by STARS. It has been accepted for
inclusion in Electronic Theses and Dissertations, 2004-2019 by an authorized administrator of STARS. For more
information, please contact STARS@ucf.edu.

STARS Citation
Salvatico, Jose, "The Expression Of Mkrn1, An E3 Ubiquitin Ligase For Telomerase Reverse Transcriptase,
Is Induced With Differentiation Therapy In Leukemia" (2009). Electronic Theses and Dissertations,
2004-2019. 4107.
https://stars.library.ucf.edu/etd/4107

THE EXPRESSION OF MKRN1, AN E3 UBIQUITIN LIGASE FOR TELOMERASE
REVERSE TRANSCRIPTASE, IS INDUCED WITH DIFFERENTIATION THERAPY IN
LEUKEMIA.

by

JOSE SALVATICO
B.S. University of Central Florida, 2004

A thesis submitted in partial fulfillment of the requirements
for the degree of Master of Science
in the Department of Molecular Biology and Microbiology
in the Burnett School of Biomedical Sciences
in the College of Medicine
at the University of Central Florida
Orlando, Florida

Fall Term
2009

Major Professor: Mark T. Muller

© 2009 Jose Salvatico

ii

ABSTRACT

Telomeres are important structural and functional components of chromosomes, serving to
provide stability and enabling full replication of the chromosomes. However, a shortening of the
telomeres occurs with each cell division that can be fixed by a polymerase activity provided by
telomerase, preventing this loss which would otherwise eventually lead to chromosome end-toend fusions, senescence and cell death. The telomerase activity is present in stem cells and germ
line cells, but absent or barely noticeable in adult somatic cells. However, in approximately 8090% of transformed somatic cells the telomerase activity is recovered, resulting in a “telomerase
positive phenotype”. This phenotype has been a prime target in cancer research, and recently a
novel mechanism for regulating telomerase levels has been uncovered. Makorin 1 RING finger
protein (MKRN1) was found to be an E3 ubiquitin ligase for hTERT, the rate-limiting catalytic
component of telomerase, leading to the ubiqutin-mediated 26s proteasomal degradation of
hTERT and reduced telomerase activity. So, MKRN1 plays a role in telomere homeostasis..

In this study we looked at the expression of MKRN1 in numerous tumor cell lines (Hela,
HCT116, HL60) and the normal diploid fibroblasts (WI-38). In the latter cell line, basal levels
of MKRN1 were found to increase 6-fold when the cells were serum starved and arrested in
G1/G0. In contrast, the cancer cell lines expressed MKRN1 at low levels or undetectable. This
would indicate that MKRN1 is up-regulated in resting or G1 arrested cells.In one cell line the
promyelocytic leukemia, HL-60, showed no protein levels of MKRN1. This cell line is able to
be terminally differentiated upon ATRA treatment, when cells are arrested at G1. In this model
iii

system of cellular differentiation hTERT mRNA levels and telomerase activity decrease
drastically and quickly. We hypothesized that the differentiation of HL-60 induced by ATRA
would be accompanied by an increase in MKRN1 levels. MKRN1 mRNA and protein levels
were strongly up-regulated during the ATRA-mediated differentiation of HL-60 cells. Although,
a decrease in hTERT mRNA is a contributor to telomerase inhibition during cellular
differentiation; our data indicate that the up-regulation of MKRN1 ensures the effective removal
of residual telomerase activity by the ubiquitin-mediated degradation pathway at the proteasome.
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CHAPTER ONE: INTRODUCTION
General Introduction
Human telomeres are nucleoprotein structures found at the ends of linear chromosomes,
consisting of a repetitious hexameric DNA sequence (5’-TTAGGG-3’) and telomere-associated
proteins. These structures preserve chromosomal stability by preventing end-to-end fusions(13), rearrangements, and nucleolytic degradation. If these events should occur, then either cell
death or tumorigenic selectivity could result(4,5). Differentiated cells lack telomerase activity
and due to the end replication problem, 150-300 base pairs of DNA are lost with each cell
division, resulting in cellular senescence, and loss of cell proliferation(5-7). However, in highly
replicative tissues, such as hematopoetic, germline and most human cancers, telomerase activity
is a token phenotype required for the cell proliferation and survival of these cells(8-11).
Telomerase is a ribonucleoprotein consisting of human telomerase reverse transcriptase (hTERT,
the catalytic protein subunit), and an RNA template, hTR, complementary to the hexameric
repeat sequence. Telomerase is responsible for maintaining telomere length by adding to the 3’end of the G-rich strand; thereby preventing erosion of the chromosome ends(5,6,8,12). Thus,
telomere homeostasis is a pacing mechanism controlling cellular replication and senescence.
There are diverse mechanisms for the regulation of hTERT and telomerase activity(13).
Transcriptional regulation of the hTERT gene is tightly controlled by numerous transcription
factors and epigenetic mechanisms(14). Activators for hTERT transcription include c-MYC,
Sp1 and estrogen response elements, and repressors include MAD1, p53, CTCF and WT1(1417). The methylation status of the hTERT promoter has an effect on how the gene is regulated
1

by affecting the binding of activators or repressors(18-22). Recent evidence in retinoiddifferentiated human leukemic cells suggests that hTERT promoter methylation occurs after
initial transcriptional repression, to further silence the gene(23). Alternative splicing has also
been implicated in regulating hTERT expression and telomerase activity in human
development(24). Although, these reports show a strong correlation between levels of hTERT
transcripts and telomerase activity, there is evidence that protein interactions and posttranslational modifications of the hTERT protein are involved as well. The phosphorylation
status of hTERT has been shown to regulate telomerase activity(25-27), and in T-lymphocytes, it
serves to regulate hTERT localization as well as activity(28). Some proteins, such as PinX1 act
as inhibitors of telomerase(29), whereas others like KIP stimulate telomerase(30). The hTERT
protein also interacts with and is stabilized by HSP90, allowing it to associate with hTR to form
the functional telomerase holoenzyme(31,32). This interaction can be blocked by treatment with
the chaperone inhibitor, geldanamycin (GA)(31). Recent studies show that GA treatment
destabilizes hTERT and promotes its ubiquitination, which leads to proteasomal degradation
efficient removal of telomerase activity(33). Furthermore, this proteolysis of hTERT could be
reversed when proteasome inhibitors were used. In the same studies, the Makorin RING Finger
Protein 1 (MKRN1) was found to interact with hTERT protein, serving as an E3 ubiquitin ligase,
and having a role in hTERT proteolysis. The effects of this interaction enhanced hTERT
ubiquitination and proteasome-mediated degradation, even in the absence of GA. In addition,
stable expression of MKRN1 promoted the loss of telomerase activity and telomere length in
telomerase positive cells, without affecting hTERT mRNA or hTR levels. Thus, a new mode of
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telomerase regulation was introduced, with MKRN1 serving as a negative regulator of the
catalytic component for telomerase activity.
In humans, MKRN1 is ubiquitously expressed in normal fetal and adult tissues, and well
conserved orthologs have been found in plants, invertebrates, and vertebrates; suggesting an
ancient origin and importance for this gene (34); however, little is known of its expression and
activity in telomerase positive cells. It has also been shown to be an E3 ubiquitin ligase for p53
and p21(35). MKRN1 was shown to affect RNA polymerase II dependent transcription both
positively and negatively (36). Here, we show that MKRN1 is expressed differently in
telomerase positive human cancer cell lines and the normal diploid fibroblast cell line, WI-38.
One cell line in particular, the HL-60 acute myeloblastic leukemia cells, had no detectable
MKRN1 protein and very low mRNA levels. However, upon All-Trans Retinoic acid induced
differentiation of these cells, MKRN1 expression is strongly activated leading to a concurrent
decrease in telomerase activity. Differentiation of HL-60 cells has been established as a tractable
model system for telomerase regulation during cellular differentiation.(23,37,38) It has been
shown that hTERT gene transcription is shut off, and recently, post-translational modifications of
hTERT have been suggested as a mechanism of down regulation(39); however, mechanistic
details are unknown at this time. Our observations suggest that induction of MKRN1 expression
contributes to the effective termination in telomerase activity and ensures effective removal of
telomerase activity during cellular differentiation.
The specific objectives within this thesis were to : 1) characterize the levels of MKRN1
in different cancer cell lines and the normal diploid fibroblasts, WI-38, to test the hypothesis that
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the expression of MKRN1 would be counter to that of hTERT and telomerase activity; 2)
determine if the expression of MKRN1 is induced in terminally differentiating HL-60 cells,
which are known to have telomerase activity and hTERT expression turned off.
Makorin1
The Makorin RING finger protein-1 gene is the founder of a family of 8 intronless mammalian
genes that encode a new class of zinc finger (ZnF) proteins. This gene can be found in fungi,
plants, C. elegans, fruit fly, chicken, mouse, humans and even in the poxviral genomes (34). For
this, it has been deemed ancient and lauded as functionally important for development. The gene
is highly transcribed in both humans and mice, and is found on chromosome 7q34 and 6A
respectively. In humans, at the mRNA level it is found uniformly in the heart, brain, placenta,
lung, liver, kidney, skeletal muscle, in both adult and fetal tissues. In mice its expression is
heterogeneous with higher levels in the testis and brain, and two splice variants are present, a 2.0
kb and a 3.2 kb version, compared to just one ~3 kb form in humans. The 3.2 kb transcript is the
predominant form in the brain, while the shorter form is expressed more in the embryo (34). The
human cDNA was found to be 3026 bp with an open reading frame from +121 to +1567,
entailing 8 exons. The first exon contains a CpG island, which also encompasses the first intron
and the proximal promoter region. Towards the upstream region of the proximal promoter
beginning at -630 bp are found a series of Alu repeats, implying that the functional components
of said promoter are found between the -630 and +1 bp region (34)(Fig1). In both humans and
mice pseudogenes have arisen, totaling 7 in humans. The hMKRN1 resembles the longer murine
MKRN1 in both size and sites for expression.
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The protein product of MKRN1 possesses a plethora of zinc fingers that are highly
conserved, four of which are C3H ZnF’s, with two of these found proximal to the N-terminus,
another medial, and one more proximal to the C-terminus, aft of the C3HC4 RING (Really
Interesting New Gene) zinc finger domain. There is also a unique Cys-His motif consisting of
C2H2CH, in the central region just before the RING domain, which may be another class of Zinc
Finger (ZnF). The human protein is 482 amino acids, weighing in at 53.3 kDa with an isoelctric
point of 4.95 (34)(Fig2). It has been shown in two separate yeast-two-hybrid screens to interact
with hTERT, the catalytic portion of telomerase, and OIP2, a component of an exosome complex
that is involved in degrading mRNA(40). While no role has been determined for its interaction
with OIP2, Mkrn1 has been shown to be a RING finger E3 ubiquitin ligase for hTERT, targeting
it for ubiquitin/26s proteasomal degradation(33). hTERT levels and activity were shown to
decrease in the human lung carcinoma cell line H1299 and the human fibrosarcoma cell line HT
1080; and in the latter case the RNA levels for hTERT and hTR were unaffected. Furthermore,
in the telomerase (-) human osteosarcoma cell line Saos-2, hTERT transfected in was degraded
when co-transfected with MKRN1. Makorin 1 levels, it seems, are regulated by autoubiquitination as well, which concurs with what is known of other RING finger proteins(41). A
mutant of MKRN1, where His 307 was changed to Glu, resulted in a non-functional protein(33).
MKRN1 has been shown to also interact and function as an E3 ubiquitin ligase for p53 and
p21.(35) In the case of p53 it only ubiquitinates p53 and mediates its degradation under normal
conditions. Once p53 is triggered to a damage response like DNA damage, MKRN1 is unable to
ubiquitinate p53. In contrast, p21 is regulated by MKRN1 by ubiquitination regardless of the
cell state. MKRN1 has also shown to have an effect, both negative and positive, on RNA
5

polymerase II dependent transcription.(36). So, MKRN1 may be serving diverse roles in the
cell.
RING Finger Proteins
RING finger proteins are a class of Ubiquitin E3 ligases that are capable of facilitating
the transfer of ubiquitin to its substrate without covalently bonding to it, and autoubiquitination(41). There are two types depending on the residue in the fifth position of the zinc
coordinating motif, RING-HC contain a Cys and RING-H2 have a His(41). The RING finger
domain in MKRN1 is of the RING-HC variety. RING finger proteins are involved in regulating
numerous cellular processes such as, the cell cycle, transcription, apoptosis, DNA repair, and
signaling(41). Mutations in or irregular regulation of these proteins has implicated them in
cancers(42,43). There have been mutations in the RING finger of BRCA1 that link it to familial
breast and ovarian cancer(44). RING finger proteins are important for cellular functions and any
misregulation can lead to a disease state(41,42).
Ubiquitination and the 26s Proteasome
Ubiquitin is a highly expressed and well conserved protein found in all eukaryotes that
plays a role in many cellular processes by post-translationally modifying proteins involved in
cell cycle progression, signal transduction, DNA repair, apoptosis, and transcriptional regulation.
This 76 amino acid polypeptide covalently binds to the ε-amino group of a lysine (K) residue on
protein substrates(44,45). There are different forms of ubiquitination; mono-,di-, multi-, and
poly-ubiquitination. Poly-ubiquitination comes in two varieties, depending on how ubiquitins
connect to each other. If the ubiquitin polymerize at K48 then it will signal for proteasome
6

degradation, but if K63 is used then a different signal is conveyed, such as relocalization(45).
The process of ubiquitinating a protein is carried out by a series of enzymes, denoted E1
(activating enzyme), E2 (conjugating enzyme) and E3 (ligase). The E1 enzyme activates an
ubiquitin protein by forming a thiol-ester bond between a Cys residue and G76 on ubiquitin in
ATP dependent fashion, prepping it for nucleophilic attack by a Cys residue in the E2 enzyme,
forming another thiol-ester bond. Finally, E3 ligases recognize the substrates and mediate the
transfer of ubiquitin from E2 to the substrate. For substrates with ubiquitin polymers of the K48
type, localization to the 26s proteasome follows(44,45).
The 26s proteasome consists of a protealytic core made up of 4 alternating α and β
heptameric rings in a barrel configuration responsible for degrading proteins in an ATP
dependent fashion, and one or two 19s multisubunit complexes that binds to the ends of the
proteasome and that recognize, de-ubiquitinate and unfold target proteins. This entire process is
important for cellular homeostasis and irregularities in it have been implicated in cancers and
hereditary diseases(45).
Telomere and Telomerase biology
Telomeres are unique heterochromatin found at the ends of chromosomes consisting of
the sequence TTAGGG repeated one or two thousand times in humans, with this G-rich strand
over-extending its partner strand(2). These telomeres are able to protect chromosomes in two
ways. One being, the vast stretch of non-coding DNA serves as a buffering zone warding coding
DNA from the end-replication problem arising from the faulty DNA duplication of the lagging
strand. However, in telomeraseless somatic cells, this barrier lasts for only 60-70 divisions as
approximately 50-100 bp are lost from the telomeres with each cell division(2,46). Once
7

telomeres are gone, it is thought that apoptosis and cell arrest take place, leading to the stoppage
of cell growth or cellular senescence (2,46,47). This process is known as M2 (mortality stage 2)
or crisis, and comes about when the shortened telomeres are no longer able to protect vital genes
from chromosomal degradation or are subject to end-to-end joining with other chromosomal
ends or double strand breaks(2,46). This leads to the second protective function of telomeres,
end-capping. The repetitive nature of the telomere enables the single-stranded 3’ G-rich
overhang to fold backward, displacing upstream regions and hybridizing with the opposite
strand, forming a D-loop and T-loop respectively. There are various proteins that participate in
end-capping, such as TRF1, involved in telomere coiling; TRF2, stabilizes T-loop; TIN2,
promotes TRF1 function; Rap1, unknown activity in humans; TPP1, recruits POT1 to telomeres;
and POT1, which binds to and protects single-stranded telomeres at the D-loop(2,3,46).
Together these proteins have been dubbed, as a protein complex, Shelterin(3).
The telomere binding protein that has been the main focus of telomere biology is the
ribonucleoprotein enzyme, telomerase. It consists of RNA, hTR, and a catalytic protein subunit,
hTERT , and is a reverse transcriptase. It is able to maintain telomere length, not extend it, by
adding bases using the hTR as a template(46). Telomerase is not present or active in somatic
cells, but is, in stem cells, germ cells and transformed somatic cells. This provides 85-90% of
tumors with the ability to forgo cellular senescence and grow indefinitely(11,46). The ability of
telomerase to maintain chromosomal ends seems not to be its only role in tumorigenesis. It has
been implicated in human mammary epithelial cells to directly induce growth-promoting
genes(48). As a client protein of Hsp90 its stability is susceptible to geladanmycin which
inhibits Hsp90 from binding proteins(32,49). This has provided an avenue of treatment against
8

telomerase (+) cells. It has been found recently that hTERT is regulated by degradation via the
26s proteasome(33).
Telomerase activity is a highly regulated and important for cellular differentiation.
During the development of blood cells, hematopoesis, telomerase activity is expressed basally in
primitive stem cells(50). When these cells are required to differentiate into different lineages of
progenitor cells telomerase activity is ramped up to accommodate the increase in cellular
proliferation to generate large pools of progenitor cells. Afterward, when these progenitor cells
are signaled to terminally differentiate into mature cells telomerase activity is down-regulated to
barely detectable levels or shut off completely(50). Since, telomerase possesses an enzymatic
activity that could prove deleterious if left on.
HL-60 cells as a model for tracking telomerase regulation in cellular differentiation
The Hl-60 cell line was derived from a single patient with acute promyelocytic
leukemia.(51) It has proved a useful tool as an in vitro model system for studying the cellular
and molecular processes involved in differentiation and proliferation of both normal and
leukemic cells of the monocyte and granulocyte lineage. These cells are blocked at an immature
stage of differentiation with the potential to proliferate indefinitely(51,52). However, these cells
can be differentiated with the treatment of certain chemicals to mature terminal cells. All-Trans
Retinoic acid (ATRA) and dimethyl sulfoxide (DMSO) can induce these cells to differentiate to
granulocytic neutrophil cells where upon they cease proliferating and eventually enter apoptosis.
(51) Treatment with Vitamin D3 and Sodium Butyrate will differentiate to monocytes , however
there is little loss of proliferation for these cells(51). So, as a differentiation therapy, ATRA
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factors as a better candidate. However, this form of therapy has not proven to be definite as
relapses are resistant to further treatment. (53)
When HL-60 cells are treated with ATRA certain characteristic changes occur. They
loose their round smooth appearance and begin to form aggregates, with these aggregates
increasing in size and number as more cells differentiate(37). Another characteristic change is a
cessation in cellular proliferation as cells first enter in G1 arrest, and finally apoptose. One
marker for differentiation,cell differentiation maker 11b (CD11b) increases with exposure to
ATRA. These events are not synchronous , with the cells first entering G1 and proliferation
ceasing , then CD11b expression is up-regulated, and aggregation occurring with increased
CD11b expression.(37)
This model system has been very tractable in following telomerase regulation.(23,37,38)
With ATRA treatment hTERT transcription is shut off early on, while telomerase activity is still
present from newly translated transcripts that are still being made and by stable and active left
over hTERT protein as transcripts disappear. Many suggest that the down-regulation and
epigenetic silencing of hTERT transcription is solely responsible for this inhibition of telomerase
activity(18,23,37). However, not much has been done to look at the regulation of the hTERT
protein in this model. One study points to phosphorylation and a decrease of hTERT protein, but
no clear mechanistic link has been made(39).
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CHAPTER TWO: MATERIALS AND METHODS
Cell Lines and Culture Conditions
The human cervical carcinoma cell line HELA was cultured in RPMI-1640 medium; the
human diploid fibroblast cell line WI-38 in Minimum Essential Media; and the human colorectal
carcinoma cell line HCT116, human embryonal kidney cell lines HEK293 and HEK293FT were
cultured in Dulbecco’s modified Eagles medium supplemented with 10% fetal bovine serum
(FBS), 100units/mL penicillin, and 100ug/mL streptomycin in 5% CO2 at 37 ºC. The human
promyelocytic leukemia cell line HL-60 were acquired from ATCC (American Type Culture
Collection, Manassas, VA) and cultured in suspension at 250,000 cells/mL with Iscove’s
modified Dulbecco’s medium supplemented with 20% FBS, 100units/mL penicillin and
100ug/mL streptomycin in 5% CO2 at 37 ºC. To induce differentiation, HL-60 cells were seeded
at 500,000 cells/mL and 10uM All-Trans Retinoic Acid (ATRA), purchased from Sigma (Sigma
Chemical Company, St. Louis, MO).
Analysis of Proliferation
For the growth curve studies, HL-60 cells were counted using Trypan blue dye exclusion
on a Neubauer Hemacytometer. Morphological changes of HL-60 cells were tracked using a
Nikon Eclipse TE200 inverted microscope.
Fluorescence-Activated Cell Sorting (FACS)
Differentiation of HL-60 cells was determined by using Fluorescence-Activated Cell
sorting (FACs) analysis of a differentiation marker for HL-60 cells, CD11b. Briefly, 1 x 106
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cells were washed three times with ice cold wash buffer (PBS containing 1% BSA) at 300 g’s
and 4ºC, and incubated with .05ug of Fluorescein Isothiocyanate (FITC) conjugated anti-CD11b
monoclonal antibody (BD Biosciences, San Jose, CA) at 4ºC for 30 minutes in the dark. Then,
cells were washed in wash buffer (1% BSA in 1 X PBS) at 300 g’s at 4ºC for 5 minutes, and
analyzed immediately using a Becton Dickinson FACScalibur flow cytometer(Becton Dickinson,
Franklin, NJ) and WinMDI 2.8 software (Joseph Trotter, Flow Cytometry Core Facility, Scripps
Research Institute, http://facs.scripps.edu.software.html). For cell cycle analysis HL60 cells
were harvested from 0-6 days, washed three times in 1mL of 1 X PBS, re-suspended in 1mL of
PBS and added slowly to 9 mL of 70% ethanol at 4ºC to be fixed. Fixed cells were then treated
with RNase and stained with propidium iodide at 20ºC for 30 minutes; and then analyzed using a
Becton Dickinson FACSCalibur flow cytometer and WinMDI software.
RNA Extraction
Total RNA was extracted from the cell using TRIZOL reagent (Invitrogen,). Cells were
centrifuged at 2000 r.p.m. for 2 minutes, resuspended in 1mL of TRIZOL reagent, and incubated
at room temperature for 5 minutes. Then, of Chloroform was added and shaken by hand for 15
seconds, and incubated for 3 minutes at room temperature. Next, the lysate was spun down at
12000 g’s for 10 minutes at 4°C and the upper aqueous phase was saved. To the aqueous phase
was added 500mL of isopropanol, then incubated at room temperature for 10 minutes, and spun
down at 12000 g’s for 10 minutes at 4°C. The pellet containing the RNA was washed in 75%
ethanol, by vortexing and centrifuging at 7500 g’s for 5 minutes at 4°C. Finally,the washed
pellet was resuspended in 30ul of RNase free water and stored at -80°C, until needed.
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Reverse Transcription and PCR Amplification
Reverse transcription of, 2ug of RNA extracted as described above, was carried out using
M-MLV Reverse Transcriptase and random primers (Promega,USA) for first-strand cDNA
synthesis. The RNA(4ul) was mixed with 1ul of the random primers and 10ul of RNase free
water, incubated at 70 °C for 5 minutes, and then put on ice. Next, 2ul of 5x M-MLV reaction
buffer, 1.5ul of 10uM dNTPS, 1ul of RNase Inhibitor, 1ul M-MLV reverse transcriptase and
4.5ul of RNase free water were mixed together and added to the RNA/primer mixture. These
were then incubated at 37 °C for 1 hour. Afterwards, the newly synthesized cDNA was stored at
-20°C until needed. One microliter of the cDNA was then used as the template for PCR
amplification using Accuprime Pfx polymerase (Invitrogen, USA). The products were
visualized by a 1% agarose gel electrophoresis and staining of the gels with ethidium bromide.
The images were captured using Syngene’s (Cambridge, UK) ChemiGenius Bio Imaging System
and digitized using their GeneTools program. PCR was performed using the primers listed on
Table 1. The conditions for PCR of each cDNA are listed in Table 2.
Western Blots
Whole Cell extracts were prepared by re-suspending cells in lysis buffer (1X PBS, pH7.5,
1% NP-40, .5% deoxycholate, .1% SDS, 10% glycerol and 1X protease inhibitor cocktail
(Roche). Following incubation on ice for 20 minutes, lysates were centrifuged at 13000 rpm for
20 minutes at 4ºC. The protein concentration was measured using the Bio-RAD Protein Assay
(Bio-RAD, California) and a Tecan GENios 96-well microplate reader; using a BSA (1mg/ml)
Standard curve. Then, the whole cell lysates were frozen at -80°C until needed. Samples were
subjected to 10% SDS polyacrylamide gel electrophoresis, and proteins were transferred to a
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nitrocellulose membrane. Anti-MKRN1 rabbit polyclonal antibody was prepared using a
commercial antibody production service (Harlan Laboratories) and was raised against MKRN1
polypeptide. β-ACTIN antibody (Sigma) was used as a loading control. Immunoreactive bands
were visualized using SuperSignal West Dura (Thermo Scientific), captured using Syngene’s
(Cambridge, UK) ChemiGenius Bio Imaging System and digitized using their GeneTools
program.
Telomeric Repeat Amplification Protocol Assay (TRAP)
For TRAP assays, cells were harvested and lysed in CHAPS lysis buffer (10mM Tris-HCl, pH
7.5, 1mM MgCl2, 1mM EGTA, 0.5% CHAPS, 10% glycerol, 0.1mM PMSF, and 5mM βmercaptoethanol). After incubating on ice for 30 minutes, lysates were centrifuged at 13,000
rpm, 4ºC for 20 minutes. CHAPS cell extracts (1ug) were added to telomerase extension
reactions, consisting of 10 X TRAP reaction buffer (200mM TRIS-HCl,pH 8.3; 15mM MgCl2;
620mM KCl; 0.05% Tween-20; and 10mM EGTA), 10mM dNTPS, and 10uM HTS primers; and
then incubated for 30 minutes at 27ºC. PCR amplification of TRAP reaction products (5ul) was
performed using: 10uM ACX and TS primers, 50mM MgCl2, 10mM dNTPS, and 2.5 units of
Taq polymerase for 30 cycles of denaturation at 94ºC for 30 seconds, annealing at 60ºC, and
extension at 72ºC for 30 seconds. 10uM NT and 1amol of TSNT primers were added to the PCR
reactions to generate an internal telomerase assay standard (ITAS). Primer sequences for the
TRAP assay are listed in Table 3. PCR products were resolved using a non-denaturing
polyacrylamide gel consisting of 12.4% acrylamide/bis-acrylamide (29:1), .5 X TBE, APS and
TEMED. The gel was run for 80 minutes at 120 V and then visualized by staining with SYBR
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Gold (Molecular Probes, USA) using the ChemiGenius Bio-Imaging system with the Epi short
wave UV light.and Short wave band filter. The signal intensity was quantified with GeneTools.
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CHAPTER THREE: RESULTS
Differential expression of MKRN1 mRNA and protein in cancer cell lines and WI-38 cells
Telomerase activity is correlated with 85-90% of all cancer cells. Since MKRN1 is a
negative regulator of hTERT, we reasoned that MKRN1 expression may be counter to hTERT in
model cancer cell lines. Using GAPDH normalized cDNAs and semiquantitative RT-PCR, we
assessed MKRN1 mRNA levels in different human cancer cell lines and the normal diploid
fibroblast cell line, WI-38 (Fig. 5)We were able to detect MKRN1 mRNA readily in all the cell
lines, although HL-60 and Hela cell lines showed the lowest overall expression patterns relative
to GAPDH. To verify that the changes in MKNR1 mRNA was not due to poor integrity of the
RNA extracts used, we checked the RNA extracts on a 1.5% agarose gel and stained with
ethidium bromide. The integrity of the 18s and 26s ribosomal RNA was of good quality(Fig.4).
We also analyzed MKRN1 protein expression using whole-cell lysates (normalized to β-Actin)
and a MKRN1 polyclonal antibody. The data show that MKRN1 protein levels were highest in
WI-38, HEK 293, Hek 293FT and HCT116 cells; low but detectable in in Hela, and undetectable
in HL-60 (Fig. 6a). Interestingly, upon serum starvation of WI-38 cells for 48 hours, MKRN1
protein levels were 6-FOLD higher relative to exponentially growing (serum fed) WI-38 cells
(Fig. 6b). This last observation shows that MKRN1 protein levels are higher in resting cells.
This result also suggests that MKRN1 expression may be related to differentiation status. This
was tested next.
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Differentiation of HL-60 cells with ATRA as a model for MKRN1 influence on telomerase
HL-60 cells terminally differentiate into neutrophils after treatment with retinoic acid
derivatives, such as ATRA. A number of alterations in morphology, gene expression and growth
characteristics are known to occur(37). Our analysis of MKRN1 expression focused on
differentiation events in the first 6 days following ATRA exposure. The number of live cells
increased continuously in control cells, whereas in ATRA treated cultures cell growth was
inhibited within 1 day. Cell proliferation remained flat over the next 6 days in the ATRA treated
cultures (Fig.8 ) and during this interval we detected increases in the fraction of dead cells, as the
population terminally differentiated into neutrophils. We also observed that after 2 days of
ATRA treatment HL-60 cells lost their smooth round appearance and formed clusters that grew
in size and number with each subsequent day; such changes in morphology were not seen in the
control cells (Fig. 7). The cell differentiation marker, CD11b, was expressed in approximately
7% of ATRA-treated cells at day 1 and 50% by day 6 (Fig. 9). Finally, we looked at the cell
cycle and found that approximately 80% of the cells were in G1 after 3 days of ATRA treatment
(Fig. 10). This last coincides with the above cessation of cell proliferation results. These data
are similar to published results on cytodifferentiation of this promyelocytic leukemia cell line.
MKRN1 mRNA and protein levels in differentiating HL-60 cells
It is well documented that hTERT expression and telomerase activity are down-regulated
upon ATRA-mediated differentiation of HL-60 cells and that telomerase activity is quite high in
undifferentiated HL-60 cells(14,37,38). Since, MKRN1 has been shown to negatively regulate
hTERT and telomerase activity and is elevated in resting cells (Fig. 6a), we predicted that
differentiation of HL-60 cells would be attended by an increase in MKRN1 expression. We
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compared MKRN1and hTERT mRNA levels in differentiating HL-60 cells by RT-PCR and
observed a slight increase in MKRN1 transcripts within 24 hr post ATRA treatment (Fig. 12).
During this period, hTERT mRNA levels were significantly reduced and by day 3-4 completely
absent (Fig. 12). To verify that the decrease in hTERT mRNA was not due to poor integrity of
the RNA extracts used, we checked the RNA extracts on a 1.5% agarose gel and stained with
ethidium bromide. The integrity of the 18s and 26s ribosomal RNA were of good quality (Fig.
11). In contrast to the sudden decrease in hTERT mRNA, the decrease in telomerase activity
appears to be more gradual, dropping sharply after days 4-5 and barely detectable by day 6 (Fig.
14). These results indicate that hTERT protein is still stable and that telomerase activity persists
as hTERT transcript levels display a precipitous decay. Under the same conditions of HL-60
differentiation, MKRN1 polypeptide levels are increasing with peak values around days 4-5, a
time when telomerase activity is sharply decreased (Fig. 13).
To further investigate these findings, we examined changes in MKRN1 levels during
short-term treatment of HL-60 cells with ATRA. MKRN1 mRNA levels did not change
significantly in the first 12 hours and then doubled by 24 hours (Fig. 16). MKRN1 polypeptide
levels were first detected at 24 hours (Fig. 17).
Effects of MG132 on telomerase activity in differentiating HL-60 cells
Previously, in H1299 cells, it was shown that the HSP90 inhibitor, GA, could destabilize
telomerase, causing hTERT protein to be susceptible to ubiquitin-mediated proteasomal
degradation and a correlative decrease in TRAP activity(33). This degradation could be
abrogated by the proteasome inhibitors, ALLN or MG132. In the same studies, ectopically
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expressed MKRN1 induced ubiquitylation of hTERT and MKRN1 stable over expression in
HT1080 cells caused a loss of TRAP activity and telomere length, even in the absence of GA.
Since MKRN1 polypeptide levels are up-regulated in differentiating HL-60 cells, we examined
the effects of MG132 treatment on telomerase activity in control and differentiated cells. There
was a 20% recovery of TRAP activity when day 3 differentiated HL-60 cells were treated with
MG132 alone; indicative that a loss in TRAP activity is not only due to the depletion of hTERT
transcripts, but also to the loss of functional telomerase enzymes through proteasomal
degradation of hTERT (Fig. 15). These observations bolster the aforementioned model for
telomerase regulation, in which MKRN1 destabilizes telomerase via ubiquitin-mediated
proteolysis of hTERT, and place it in the context of a biological event, the granulocytic
differentiation of HL-60 cells.
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CHAPTER FOUR: DISCUSSION
In previous studies from this lab, MKRN1 was shown to induce the ubiquitin-mediated
proteolysis of hTERT (33). In this study the following can be drawn up. Under physiological
conditions hTERT interacts with HSP90 and moves into the nucleus to associate with hTR
forming telomerase; and maintaining the telomeres. When GA is added to cells the association
between hTERT and HSP90 is abrogated and hTERT ubiquitination is induced and it is localized
to the 26s proteasome for degradation. Also, in the absence of GA, ectopic MKRN1 is able to
mediate ubiquitination of hTERT mediating its proteasomal degradation (Fig. 3).To investigate
this model of telomerase regulation under physiological conditions, we looked at the ATRAmediated differentiation of HL-60 cells, in which much work has been done focusing on the
inhibition of telomerase activity. In differentiated HL-60 cells hTR does not seem to be factor in
the decrease in telomerase activity (54). The rate-limiting component appears to be hTERT.
There is much evidence that links hTERT gene expression to telomerase activity in cellular
differentiation (23,37,50,55,56). However, little work has been done looking at the regulation
and turnover of hTERT at the protein level, and how this contributes to the inhibition of
telomerase activity. Recently, studies point to post-translational modifications, such as
phosporylation, and a decrease in hTERT protein, as contributing (39,56). We report that
MKRN1 expression is significantly activated during terminal differentiation of HL-60 cells,
which can be detected as early as day 1 for MKRN1 protein and 12 hours for MKRN1 mRNA
post ATRA treatment. The activity of MKRN1 on hTERT may be a necessary part in regulating
telomerase activity in somatic cell differentiation based on these data. First, MKRN1 expression,
both mRNA and protein, are up-regulated early on in differentiation as decreases in telomerase
20

activity are detected (Fig. 16, Fig.17). Even though hTERT transcription is shutoff early on,
there is still telomerase activity present, either from de novo translation as transcription is being
turned off, or from leftover stable and active hTERT protein. We also note that recent studies
show hTERT protein disappearing after day 3 of ATRA treatment of HL-60 cells (39), when
MKRN1 levels peak (Fig.13). Furthernore, with MG132 treatment, the recovery in telomerase
activity is indicative that the inhibition of telomerase activity seen is not only from the
exhaustion of hTERT transcripts, but also the ubiquitin-mediated degradation of hTERT protein.
The up-regulation of MKRN1 by ATRA may play an important role in the cytodifferentiation of
HL- 60 cells; notably, the down-regulation of hTERT protein. Cells may have evolved this
mechanism to prevent an enzymatic activity from performing a function, telomere
elongation,that is no longer necessary in terminally differentiated cells MKRN1 function would
serve, then, to prevent irreversible extension of telomeres.
Looking at the data from the MKNR1 protein levels from the different cell lines suggests that
there is an opposite relationship between MKRN1and hTERT. Diploid fibroblasts have been
reported to contain very low telomerase activity and hTERT protein(57). So, it’s of interest to
find MKRN1, an E3 ubiquitin ligase for hTERT, in early passage WI-38 cells. This supports the
findings of an active telomerase in normal diploid fibroblasts. MKNR1 is a protein that is upregulated in cells that are undergoing G1 arrest or quiescence as evidenced here in serum starved
resting WI-38 cells (Fig 6) and in G1 arrested differentiated HL-60 cells (compare Fig. 13 and
Fig.10). This is expected considering that it targets hTERT, a protein necessary for active
cellular proliferation. In immature, hematopoietic stem cells telomerase activity is expressed at
basal levels, where upon activation of these cells to proliferate as progenitor cells, telomerase
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activity is up-regulated. Once the signal to differentiate to mature cells is given telomerase is
down-regulated (50). The HL-60 cells represent a type of progenitor cell that is blocked in the
proliferative stage. But it can become terminally differentiated to a mature neutrophil with
ATRA. Recently, MKRN1 has been shown to be an E3 ubiquitin ligase for p53 and p21 (35),
both proteins important for proper cell cycle regulation and cellular development. The study
found that when U2OS cells were depleted for MKRN1, cell death decreased. Presumably, this
occurs by MKRN1 inhibiting the role of p21 in inhibiting apoptosis. HL-60 cells are p53 Null,
but p21 is expressed (58). Moreover, p21 levels are up-regulated upon ATRA-induced
granulocytic differentiation of HL-60 cells (59) Constitutively active, p21 can maintain cells in a
permanent cellular senescence (60). However, neutrophils are short-lived, lasting a few hours to
a few days. Although, p21 is present to maintain the cells in G1, MKRN1 is also up-regulated
and may be acting on p21 as well to help induce apoptosis, by ubiquitinating p21 and mediating
its proteasomal degradation. So, MKRN1 maybe involved in more than one role in the cellular
differentiation of HL-60 cells, given that MKRN1 is a well conserved gene emphasizing a role in
cell growth processes.
In summary, we provide an additional mechanism of regulating telomerase activity,
whereby MKRN1 promotes the ubiquitin-mediated proteolysis of hTERT to ensure the full
inhibition of telomerase activity during differentiation. In this scenario, in undifferentiated and
cycling HL-60 cells, hTERT is not degraded and is able to maintain the telomeres; however, with
differentiation therapy (ATRA) hTERT is ubiquitinated by MKRN1 localizing it to the 26s
proteasome for degradation(Fig.18). Importantly, we think MKRN1 expression could be used as
a marker indicative as to whether strategies targeting the stability and degradation of
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hTERT/telomerase, such as GA or differentiation therapy, would be successful for the treatment
of certain cancers. Differentiation therapy has been used with APL, however, there is an
incidence of resistance to the treatment (53). Perhaps treatment with GA can provide another
avenue either alone, or in combination with differentiation therapy, of treating leukemias, given
that hTERT is necessary for proliferation and highly sensitive to degradation with GA treatment
(33).
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Figure 1 The structuref the MKRN1 gene
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Figure 1
The MKRN1 gene is comprised of 8 exons, 7 introns and contains a CpG island that runs from
the proximal promoter region and through the first exon and into the first intron
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Figure 2 The strucutre of the MKRN1 protein
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Figure 2
The MKRN1 protein consists of 4 C3H zinc fingers, a RING zinc finger domain which possesses
the E3 ligase activity, and the MKRN1 Family Cys-His domain which may be a novel type of
zinc finger.
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Figure 3 Schematic Model of MKRN1 Regulation of hTERT
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Figure 3.
hTERT interacts with HSP90 which stabilizes hTERT and allows it to associate with hTR in
order to carry out telomere maintenance (Yellow arrows). When Geldenamycin, an HSP90
inhibitor, or MKRN1 are added hTERT ubiquitination is induced which localizes to the 26s
proteasome to be degraded (Red arrows).
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Figure 4 Electrophoresis analysis of total RNA displaying intact ribosomal RNA

30

Figure 4
Total RNA (1ug) was checked on an 1.5% agarose gel stained with Ethidium Bromide (.5ug/mL)
for the cell lines indicated. The integrity of 18s and 28s ribosomes was shown to be intact,
indicating that the RNA used for the cDNA synthesis and PCR was of good quality.
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B

Figure 5 . Differential expression of MKRN1 mRNA in tumor cell lines and WI-38 cells.
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Figure 5
(A)Expression of MKRN1 mRNA in the indicated tumor cell lines and diploid fibroblast cell
line WI-38. All cDNAs were normalized to GAPDH mRNA expression and analyzed using
semi-quantitative RT-PCR. GAPDH was used as the internal control and relative MKRN1
expression levels to GAPDH are shown graphically (MKRN1/GAPDH). (B)The graphical
values represent the mean and ± SD of three independent experiments.
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B

Figure 6 Differential expression of MKRN1 protein in tumor cell lines and WI-38 cells.
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Figure 6
(A)Whole cell lysates were normalized to β-ACTIN levels and MKRN1 polypeptide levels were
determined using anti-MKRN1 polyclonal antibody. β-ACTIN was used as the internal control
and the relative MKRN1 expression levels to β-ACTIN are shown graphically (MKRN1/ βACTIN). WI-38 cells were early cycling cells, WI-38(-) serum, are WI-38 cells fed only 0.2 %
Serum for 2days. (B) The graphical values are representative of three independent experiments.
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Figure 7 Morphological changes to HL-60 cells treated with ATRA
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Figure 7
ATRA affects the morphology and behavior of HL-60 cells. Cells were treated with 10uM
ATRA and changes in the smooth round appearance and clumping of cells were observed as
early as day 3 and increasing in prominence by day 6. Such morphology changes were not seen
in the control cells.
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Figure 8 Changes in Proliferation Rate of ATRA treated HL-60 cells
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Figure 8
Cells were treated with 10uM ATRA for 6 days and the total number of live cells were counted
daily (0-6 days). The cells were re-seeded every two days with fresh media and fresh ATRA.
Cells treated with ATRA stopped growing while control cells were unaffected and continued to
proliferate. The values represent the mean and ±SD of three independent experiments.
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Figure 9 CD11b expression in HL-60 cells treated with ATRA
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R2

Figure 9
CD11b expression, a marker of granulocytic differentiation, was measured after 10uM ATRA
treatment of cells and incubated with a CD11b antibody conjugated to FITC. (A)HL-60 cells
were incubated with 0.05ug of anti-CD11b conjugated to FITC. Control unstained and RA
unstained were both used to set the gating threshold value (.3%). (B)The percentage values
represent the proportion of CD11b-positive HL-60 cells as determined by Fluorescent Activated
Cell Sorting (FACS). Con cd11b, untreated cells stained with FITC; con Unstained, untreated
cells not stained with FITC; unstained, ATRA treated cells unstained with FITC. The values
represent the mean and ±SD of three independent experiments.
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Figure 10 Cell cycle distribution in HL-60 cells after induction by ATRA.
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Figure 10
HL-60 cells were treated with 10uM ATRA from 0-6 days and incubated with Propidium Iodide
to stain DNA. The DNA content was measured by FACS analysis. The percentage of cells in
G1/G0 increased with induction of differentiation by ATRA. The values represent the mean and
±SD of three independent experiments.
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Figure 11 Electrophoresis analysis of total RNA displaying intact ribosomal RNA
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Figure 11
HL-60 cells were treated with 10uM ATRA for 0-4 days and the total RNA was extracted. Total
RNA (1ug) was checked on a 1.5% agarose gel stained with Ethidium Bromide (.5ug/mL). The
integrity of 18s and 28s ribosomes was shown to be intact, indicating that the RNA used for the
cDNA synthesis and PCR was of good quality.
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Figure 12 Expression of MKRN1 and hTERT mRNAs in HL-60 cells treated with ATRA

s
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Figure 12
MKRN1 and hTERT mRNAs were detected using semi-quantitative Reverse Transcriptase to
synthesize cDNA and then amplified using PCR from HL-60 cells treated with 10uM ATRA for
0-4 days. GAPDH was used as the internal control.
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.
Figure 13 MKRN protein expression in HL60 cells treated with ATRA
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Figure 13
(A)MKRN1 protein levels from cell extracts (30ug) were checked by Western blot using a rabbit
polyclonal antibody (at a 1:2000 dilution) targeting MKRN1 from HL-60 cells treated with
10uM ATRA. Β-ACTIN was used as an internal control. (B) The relative MKRN1 expression
levels to β-ACTIN are shown graphically (MKRN1/ACTIN). The values represent the mean and
±SD of three independent experiments.
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Figure 14 The telomerase activity of HL-60 cells treated with ATRA
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Figure 14
HL-60 cells were treated with 10uM ATRA for 0-5 days , harvested and lysed with 1X CHAPS
lysis buffer. The telomerase activity of these cells was measured using the TRAP assay.
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Figure 15 The effect of MG132 on TRAP activity in HL-60 cells treated with ATRA
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Figure 15
HL-60 cells
Control cells were untreated HL-60 cells that were lysed in 1 X CHAPS lysis buffer. RA3 were
HL-60 cells that were treated 10uM ATRA for 3 days and lysed in 1X CHAPS lysis.
RA3+MG132 were HL-60 cells treated for 3 days with 10uM ATRA and then co-treated with
10uM MG132, a proteasome inhibitor, for 8 hours. The telomerase activity of these cells were
then measure using the TRAP assay.
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Figure 16 MKRN1 and hTERT mRNA level during early differentiation in HL-60 cells
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Figure 16
(A)MKRN1 and hTERT mRNA levels were checked using semi-quantitative Reverse
Transcriptase and PCR in HL-60 cells treated with 10uM ATRA from 0-24 hours. GAPDH was
used as the internal control. (B) The relative MKRN1 expression levels to GAPDH are shown
graphically (MKRN1/GAPDH). The values represent the mean and ±SD of three independent
experiments.
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Figure 17 MKRN1 protein expression levels during the early differentiation of HL-60 cells
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Figure 17
HL-60 cells were treated with10uM ATRA for 0-24 hours. To see if MKRN1 protein was
present at these early time points, a higher amount of protein (60ug) was used on a 10% SDSPAGE gel. MKRN1 protein levels were checked using a Rabbit-polyclonal antibody targeting
MKRN1 at a dilution of 1:500 by Western blot. β-ACTIN was used as the internal control.
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Figure 18 MKRN1 mediated proteolysis of hTERT during HL-60 differentiation
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Figure 18. A schematic of the mechanism for MKRN1-mediated proteolysis of hTERT during
ATRA induced differentiation of HL-60 cells. Under cellular proliferation no MKRN1 is present
so hTERT is able to form a stable telomerase enzyme and maintain the telomeres. When HL-60
cells are treated with ATRA, MKRN1 is up-regulated and is able to ubiquitinate hTERT,
localizing it to the 26s proteasome for degradation.
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Table 1 List of primers used for PCR

Oligo(dT) Primers were ordered through Integrated DNA Technology

Gene

Tm
Direction (°C)

Primer Sequence

MKRN1 Forward

55.3 5’- GAT CCC CAC AGT CAC CG-3’

MKRN2
hTERT
hTERT
GAPDH
GAPDH

50.7
56.9
56.6
57.7
58.6

Reverse
Forward
Reverse
Forward
Reverse

5’- GAT GAC TTT GTA GTT AGC TCT G-3’
5’-CGG AGG AGT GTC TGG AGC AA-3’
5’-GGA TGA AGC GGA GTC TGG A-3’
5'ACC ACA GTC CAT GCC ATC AC-3'
5'-TCC ACC ACC CTG TTG CTG TA-3'
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Table 2 The conditions used for PCR

Gene
MKRN1
hTERT
GAPDH
95°C
15s
95°C
15s
95°C 15s
Denaturation
56°C 30s
56°C 30s
58°C 30s
Annealing
68°C 30s
68°C 30s
68°C 30s
Elongation
288 bp
150 bp
450 bp
Product Size
30
20
20
Cycles
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Table 3 Dilutions of antibodies used for Western Blots

Protein

Rabbit Polyclonal Antibody

Secondary Anti-Rabbit

MKRN1

1:2000

1:5000

Β-ACTIN

1:2000

1:5000
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Table 4 Primers used for TRAP assay

Primer
Name
HTS
ACX

Tm
(°C)
Primer Sequence
53.6 5'-AATCCGTCGAGCAGAGTT-3'
66.4 5'-GCGCGGCTTACCCTTACCCTTACCCTAACC-3'
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